nasopharyngeal carcinoma (NPC, also known as “Canton Tumor”) 鼻咽癌 (俗稱「廣東瘤」)
nasopharyngeal carcinoma (NPC, also known as “Canton Tumor”)
繁: 鼻咽癌 (俗稱「廣東瘤」)
簡: 鼻咽癌 (俗称「广东瘤」)
鼻咽癌一直被稱為「廣東瘤」。中大醫學院病理解剖及細胞學系羅國煒向本報表示,新藥針對誘發癌症的EB病毒,「講廣東話先有的鼻咽癌,接近100%是因為EB病毒引致」。
「廣東瘤」元兇100%涉EB病毒 新藥適用 (2024年6月21日)。香港經濟日報,取自https://t.ly/TDcz3
Researchers at the Chinese University’s medical school have developed a new type of mRNA-based drug to treat the most common cancer among Hong Kong men aged 20 to 44 – nasopharyngeal carcinoma. Also known as the “Canton tumor,” NPC is a distinct type of head and neck cancer with the highest incidence rates reported in southeast Asia and southern China.
CUHK researchers develop new treatment for ‘Canton tumor’ (2024, Jun 21). The Standard. Retrieved from https://www.thestandard.com.hk/section-news/section/4/263796/CUHK-researchers-develop-new-treatment-for-‘Canton-tumor‘